BACKGROUND: Consistent patterns of reduced cortical thickness have been identified in early Alzheimer's disease (AD). However, the pathological factors that influence rates of cortical thinning within these AD signature regions remain unclear. METHODS: Participants were from the Insight 46 substudy of the MRC National Survey of Health and Development (NSHD; 1946 British birth cohort), a prospective longitudinal cohort study. Linear regression was used to examine associations of baseline cerebral β-amyloid (Aβ) deposition, measured using florbetapir positron emission tomography, and baseline white matter hyperintensity volume (WMHV) on MRI, a marker of cerebral small vessel disease, with subsequent longitudinal changes in AD signature cortic...
AbstractIntroductionWe aimed to investigate if thinner cortex of the Alzheimer's disease (AD)-signat...
Introduction Both beta‐amyloid (Ab) deposition and decline in white matter integrity, are brain alt...
Alzheimer’s disease (AD) has a long preclinical phase, beginning decades prior to the onset of demen...
Introduction Cortical thickness has been proposed as a biomarker of Alzheimer's disease (AD)– relat...
INTRODUCTION: Cortical thickness has been proposed as a biomarker of Alzheimer's disease (AD)- relat...
Introduction: Cortical thickness has been proposed as a biomarker of Alzheimer�s disease related n...
Background and Purpose— We assessed cross-sectional and longitudinal relationships between whole ...
Defining a signature of cortical regions of interest preferentially affected by Alzheimer disease (A...
The biological mechanisms that link Beta-amyloid (Aβ) plaque deposition, neurodegeneration, and clin...
ImportanceCriteria for preclinical Alzheimer disease (AD) propose β-amyloid (Aβ) plaques to initiate...
Alzheimer's disease (AD) is associated with neurodegeneration in vulnerable limbic and heteromodal r...
AbstractIntroductionRecent studies have shown that pathologically defined subtypes of Alzheimer's di...
OBJECTIVE: To identify a cortical signature pattern of cortical thinning in familial Alzheimer disea...
Background: Previous autopsy studies have demonstrated a high prevalence of widespread Alzheimer's d...
Cross-sectional studies have shown regional differences in cortical thickness between healthy older ...
AbstractIntroductionWe aimed to investigate if thinner cortex of the Alzheimer's disease (AD)-signat...
Introduction Both beta‐amyloid (Ab) deposition and decline in white matter integrity, are brain alt...
Alzheimer’s disease (AD) has a long preclinical phase, beginning decades prior to the onset of demen...
Introduction Cortical thickness has been proposed as a biomarker of Alzheimer's disease (AD)– relat...
INTRODUCTION: Cortical thickness has been proposed as a biomarker of Alzheimer's disease (AD)- relat...
Introduction: Cortical thickness has been proposed as a biomarker of Alzheimer�s disease related n...
Background and Purpose— We assessed cross-sectional and longitudinal relationships between whole ...
Defining a signature of cortical regions of interest preferentially affected by Alzheimer disease (A...
The biological mechanisms that link Beta-amyloid (Aβ) plaque deposition, neurodegeneration, and clin...
ImportanceCriteria for preclinical Alzheimer disease (AD) propose β-amyloid (Aβ) plaques to initiate...
Alzheimer's disease (AD) is associated with neurodegeneration in vulnerable limbic and heteromodal r...
AbstractIntroductionRecent studies have shown that pathologically defined subtypes of Alzheimer's di...
OBJECTIVE: To identify a cortical signature pattern of cortical thinning in familial Alzheimer disea...
Background: Previous autopsy studies have demonstrated a high prevalence of widespread Alzheimer's d...
Cross-sectional studies have shown regional differences in cortical thickness between healthy older ...
AbstractIntroductionWe aimed to investigate if thinner cortex of the Alzheimer's disease (AD)-signat...
Introduction Both beta‐amyloid (Ab) deposition and decline in white matter integrity, are brain alt...
Alzheimer’s disease (AD) has a long preclinical phase, beginning decades prior to the onset of demen...